Paper Details 
Original Abstract of the Article :
Sotalol and flecainide are used as second line agents in children for the treatment of supraventricular arrhythmias (SA) refractory to anti-beta adrenergic antiarrhythmics or digoxin. Efficacy and adverse events in this cohort have not been well described. Here, we report our institutional experienc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/jce.15077

データ提供:米国国立医学図書館(NLM)

Second-Line Medications for Supraventricular Arrhythmias in Children: A Comprehensive Assessment

The realm of [pediatric cardiology] is constantly seeking to improve treatment options for [supraventricular arrhythmias (SA)]. This study focuses on [sotalol] and [flecainide], commonly used as [second-line agents] in children with [SA] refractory to conventional therapies. The authors meticulously investigate the efficacy and safety of these medications in this specific patient population, shedding light on their clinical impact. This research provides valuable insights for clinicians making treatment decisions for children with [SA].

Navigating the Complexities of Pediatric Cardiology

The authors acknowledge the unique challenges associated with treating [SA] in children. They highlight the need for careful consideration of [drug efficacy] and [adverse events], particularly in this vulnerable population. This study provides valuable data to guide clinicians in their efforts to provide optimal care for children with [SA].

The Importance of Evidence-Based Medicine

This research underscores the significance of evidence-based medicine in pediatric cardiology. By systematically evaluating the efficacy and safety of [sotalol] and [flecainide] in children, the authors contribute to the growing body of knowledge that informs clinical decision-making. This research is like a beacon in the vast desert of medical knowledge, illuminating the path to more effective and safer treatments for children with [SA].

Dr.Camel's Conclusion

This study serves as a reminder that the journey of providing optimal care for children with [SA] is a continuous one. By rigorously evaluating new treatment options and understanding their potential impact, we can continue to pave the way for better outcomes and brighter futures for these young patients. Let us all be like the desert nomads, constantly seeking knowledge and sharing it to guide our path towards better health.

Date :
  1. Date Completed 2021-10-20
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

33969576

DOI: Digital Object Identifier

10.1111/jce.15077

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.